Apogem Capital’s Amedisys AMED Stock Holding History

Apogem Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,540	Closed	-$230K	–	176
2021 Q3	$230K	Buy	+1,540	New	+$320K	0.15%	165

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Apogem Capital's AMED Position: Q4 2021 in Review

Apogem Capital sold out of Amedisys (AMED) in Q4 2021, closing a stake of 1,540 shares — an estimated $230K sold.

Apogem Capital first reported a position in AMED in Q3 2021 and held it in 1 quarter. The position peaked at $230K in Q3 2021. 324 funds tracked by Wall St. Rank hold AMED as of Q4 2021.

Apogem Capital reported no remaining Amedisys position as of Q4 2021 after selling out during the quarter.
Apogem Capital sold 1,540 Amedisys shares in Q4 2021, an estimated $230K.
Apogem Capital first reported a position in Amedisys in Q3 2021 and held it in 1 quarter.
Apogem Capital's Amedisys position peaked at $230K in Q3 2021.
324 funds tracked by Wall St. Rank held Amedisys as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.